&w=3840&q=100)
Lupin, Sino Universal sign agreement to launch Tiotropium DPI in China
Tiotropium DPI is used to treat chronic obstructive pulmonary disease (COPD).
As part of the agreement, SUP will be responsible for securing regulatory approvals in China to sell the Tiotropium DPI. Meanwhile, Lupin will hold the marketing authorisation and manage the product's manufacturing.
Focus on COPD treatment and access
Tiotropium DPI is recognised for its ability to help patients with respiratory diseases by improving lung function and quality of life. This partnership supports Lupin's efforts to widen its reach in China, ensuring people have timely access to effective and reliable healthcare treatments, particularly as respiratory illnesses rise.
Wang Li, President of SUP, added, "We are truly honoured to partner with Lupin, a global pharmaceutical leader, on Tiotropium DPI. Lupin's deep commitment to respiratory disease treatment and its innovation-driven approach to high-quality products align perfectly with SUP's strategic vision. We believe this collaboration will strengthen our synergy in respiratory care. By bringing more efficient and superior products to market, we aim to make significant breakthroughs in respiratory disease treatment in China, allowing more patients to benefit from international high-quality and innovative products and enjoy respiratory health."
Lupin Limited, headquartered in Mumbai, India, is a global pharmaceutical company focused on a wide range of products, including branded and generic medicines, complex generics, biotechnology products, and active pharmaceutical ingredients. Sino Universal Pharmaceuticals, based in China, is a global one-stop pharmaceutical distribution and management service provider with over 18 years of experience.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
8 minutes ago
- Indian Express
Apple's tariff-fueled iPhone sales surge raises doubts about sustainability
Apple's best revenue growth in three years failed to impress, with shares down about 1% in volatile trading on Friday, as investors questioned whether a tariff-driven surge in iPhone sales would last. A rush to buy iPhones ahead of potential U.S. tariff-driven price increases, along with China subsidies and upbeat demand for the budget 16e model launched in February, fueled a 13.5% jump in the quarterly sales of the device, crushing expectations. That pushed up total revenue by a better-than-expected 10% in the April-June period, and Apple issued an above-estimate sales forecast for the current quarter ending in September. The results came at a precarious time for the company long seen as Big Tech's safest bet. Beyond the tariff threats facing its manufacturing hubs China and India, Apple has been slow to move on artificial intelligence technology that its software and devices rivals have embraced as their next big growth driver. Analysts said the sales rebound in China, where local rivals have moved faster than Apple on AI features, was a positive. The company benefited in the world's largest smartphone market from a state subsidy program meant to prop up device sales. But they also warned the 'pull-in' boost was expected to be temporary, raising doubts about demand for the rest of the year. 'Pull-forward, remember, is not a U.S. issue. It's also a China issue. There, Apple's Pro model iPhones were too expensive to qualify for Chinese government subsidies that were being offered … so they cut prices to qualify, leaning into the volume opportunity. It worked,' MoffettNathanson analysts said. 'But as with the U.S., what does that mean for the rest of the year?' So far this year, Apple stock has underperformed all its 'Magnificent Seven' peers barring Tesla, with a decline of more than 17%. The S&P has risen 7.8% in the period Many of Apple's products are currently exempt from tariffs, and the company has also been rebalancing its supply chain to shield itself from the duties, sourcing iPhones from India and other products such as Macs and Apple Watches from Vietnam. The U.S. is currently negotiating trade deals with both China and India, with U.S. President Donald Trump saying India could face 25% tariffs as early as Friday. Apple said tariffs would raise costs by $1.1 billion in the current quarter after the company said it took an $800 million hit from tariffs in the third quarter. Its AI strategy also remains a concern after Apple delayed the release of an AI-enhanced version of Siri virtual assistant and was slow to launch Apple Intelligence. CEO Tim Cook said on Thursday the company was making good progress on Siri and that Apple is 'significantly growing' its investments in AI. 'Brand loyalty gives Apple time to get the AI transition right, but it needs to start delivering,' said Matt Britzman, senior equity analyst, Hargreaves Lansdown.
Time of India
an hour ago
- Time of India
From shopfloor to C-suite: Mahindra offers Diwali Esops to 14,000 employees
The Mahindra Group has announced a one-time employee stock ownership plan (Esop) grant for 12,000-14,000 employees, including shop floor workers for the first time ever. The move across three core companies—Mahindra & Mahindra (auto and farm sector), Mahindra Electric Automobile and Mahindra Last Mile Mobility —comes amid surging sales and profit on the back of hit products such as the Thar driving the M&M stock up more than 12 times in five years. Mahindra has also overtaken Hyundai to become the country's second biggest manufacturer of passenger vehicles, thanks to its range of SUVs. The Esops will help broad-based wealth creation, the tractor-to-technology conglomerate said in an internal circular. ET has seen the note. It did not reveal how many shares the group will earmark for this purpose, but people in the know estimate the total outflow to be in the range of ₹ 400-450 crore. While granting Esops to keep employees motivated is not unusual, this could be the first time a large Indian conglomerate extends these benefits to shopfloor workers. The Esops, structured as restricted stock units (RSUs). Productivity Boost? The grant is being positioned as a reward for long-term contribution and a tool to align employees with value creation. 'This special grant reflects the organisation's appreciation for your efforts, makes you a co-owner of this enterprise, and gives you a share in the value that you have helped co-create,' said Anish Shah, group chief executive and managing director of M&M, in a note to employees. Rajiv Agarwal, department chair for strategy at leading B-school SPJMR, said with this move, Mahindra is fostering a productive environment, where labour participation drives higher overall productivity. 'This approach not only supports the company's growth but also allows employees to benefit from the rise in the stock price,' Agarwal said. 'It's a smart strategy — compensating workers not just with their salaries for the hours they work, but also rewarding them when the company does well. This dual benefit truly aligns employees' interests with the company's success.' The Esop scheme comes on the back of a sharp surge in valuations of Mahindra Electric and Mahindra Last Mile as well. Both have seen over 10x growth in the past five years, supported by strong execution, strategic focus and new business momentum. M&M's shares closed at ₹ 3,160 on the BSE on Friday, down 1.35 per cent from its previous close. Its market cap stood at ₹ 3,92,925 crore. The Esop shares will be granted to employees on permanent payrolls with at least 12 months' tenure in the group as of the announcement date. Depending on their income tax bracket, the beneficiaries may have to pay tax on the profits they make when they sell their Esop shares. However, shopfloor workers who earn below the taxable income limit won't have to pay any tax on these gains. The Mahindra Group communication credited executive chairman Anand Mahindra and executive director Rajesh Jejurikar for steering the transformation, while thanking employees' families and retired leaders for their support.
Hans India
2 hours ago
- Hans India
US tariff-hit stocks weigh on key indices
Mumbai: Equity benchmark indices-Sensex and Nifty- declined sharply for the second straight session on Friday, tracking deep losses in pharma, metal, and IT stocks amid trade-related concerns and widespread selling pressure in global markets. Besides, persistent selling by foreign investors added to the gloom, according to experts. In a volatile trade, the 30-share BSE Sensex tumbled 585.67 points or 0.72 per cent to settle at 80,599.91. During the day, it dropped 690.01 points or 0.84 per cent to 80,495.57. As many as 2,712 stocks declined while 1,306 advanced and 151 remained unchanged on the BSE. The 50-share NSE Nifty declined 203 points or 0.82 per cent to 24,565.35. 'The benchmark index Nifty wrapped up its fifth consecutive week in the red -- its longest losing streak since August 2023, raising eyebrows across the making multiple attempts to scale up, the index has struggled to hold ground, only to be met with selling pressure each time. The long upper wicks are a telling story — bulls tried, but bears had the final say,' Sudeep Shah, Head - Technical Research and Derivatives at SBI Securities, said.
